Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH
CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate
Company enlists Patti LaBelle to increase awareness for the pneumococcal pneumonia vaccine
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
To drive the point home, the ads even feature an image of an actual case of shingles. The blistering red rash appears on-screen for several seconds.
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups.
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs
Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts
Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed
The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
Merck CEO says industry needs to better communicate value; procedural vote could clear Califf as FDA chief; HPV vaccine lowers virus' prevalence
Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise
The former MSL regional leader reemerges as head of communications at Japan's largest pharma company.
Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.
GSK awards its global media buying business; one-third of patients dropped out of Xenoport psoriasis trial; an experimental drug for liver disease fails to meet primary endpoints